Apimeds Pharmaceuticals US, Inc
Market Cap
$2.36M
P/E Ratio
-4.59
EPS
$-0.41
Dividend Yield
0.00%
52-Week Range
$1.61 — $40.31
Volume
31.52K
Avg Volume
22.52K
Beta
-1.37
Get alerted when APUS hits your target price.
Free — enter your email to get started
P/E (TTM)
-4.59
Forward P/E
—
PEG Ratio
0.01
P/S (TTM)
0.00
P/B (TTM)
0.29
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-1.40%
ROA (TTM)
-0.56%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.06
Current Ratio
8.34
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.20%
EPS Growth (5Y)
-0.15%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
—
EPS Est (Next Year)
—
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$5.56
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
12.58M
Float
2.27M
Free Float %
18.01%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
AMEX
IPO Date
2025-05-09
Employees
2
CEO
Vinod Menon
Index Membership
—
Website
https://www.apimedsus.com
Apimeds Pharmaceuticals US, Inc (APUS) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the AMEX. With a market capitalization of $2.36M, a P/E ratio of -4.59, APUS is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare APUS against other stocks using dozens of fundamental and technical filters.
DHB.V
Delivra Health Brands Inc.
$0.15
+0.00%
$4.69M
HASH.V
Simply Solventless Concentrates
$0.04
+0.00%
$5.20M
PCLO.V
PharmaCielo Ltd.
$0.06
+20.00%
$11.28M
SXTC
China SXT Pharmaceuticals, Inc.
$2.07
+0.49%
$1.60M
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
$0.69
-32.84%
$740.65K
CHLL.L
Chill Brands Group PLC
$0.40
+0.00%
$2.09M
Apimeds Pharmaceuticals US, Inc (APUS) has a trailing twelve-month (TTM) P/E ratio of -4.59. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Apimeds Pharmaceuticals US, Inc (APUS) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Apimeds Pharmaceuticals US, Inc (APUS) has a market capitalization of $2.36 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.